Furthest ahead in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...

Two other oral BTK inhibitors in development for MS – Merck KGaA’s evobrutinib and Sanofi’s tolebrutinib – have been linked to liver toxicity that resulted in the FDA placing them on ...

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

而这是首个也是唯一一个显示非复发继发性进行性多发性硬化症（MS）残疾积累减少的研究。 据悉，非复发继发性进行性多发性硬化症目前尚无获得 ...

The current standard of care for an MS relapse involves either a five ... the parent company of Clinical Trials Arena. "Roche ...

Oditrasertib, which blocks the inflammatory RIPK1 protein, earlier this year also failed a Phase II trial in amyotrophic ...

As mentioned earlier, scientists think these immune cells play a big part in the development of MS. It looks like BTK inhibitors can get into the central nervous system. We need more research ...

This update comes just days after Sanofi shared mixed results from its BTK inhibitor, tolebrutinib ... In December 2023 the FDA put fenebrutinib’s MS programme under partial clinical hold ...

A key focus will be the results from large phase 3 trials of BTK inhibitors such as tolebrutinib, which are eagerly anticipated by the MS community. Additionally, there may be discussions on ...

The BTK inhibitors market has experienced significant dynamics driven by advancements in oncology and autoimmune disease treatments. One of the primary drivers of the BTK inhibitors market is the ...